Cargando…
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer (mPC) remains cytotoxic chemotherapy. In 2016, mor...
Autores principales: | Ghosn, Marwan, Ibrahim, Tony, Assi, Tarek, El Rassy, Elie, Kourie, Hampig Raphael, Kattan, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155171/ https://www.ncbi.nlm.nih.gov/pubmed/28028360 http://dx.doi.org/10.3748/wjg.v22.i46.10124 |
Ejemplares similares
-
Immunotherapies in sarcoma: Updates and future perspectives
por: Ghosn, Marwan, et al.
Publicado: (2017) -
Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature
por: Ghosn, Marwan, et al.
Publicado: (2016) -
The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience
por: Kattan, Clarisse, et al.
Publicado: (2020) -
Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy
por: Kourie, Hampig Raphael, et al.
Publicado: (2015) -
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
por: Kourie, Hampig Raphael, et al.
Publicado: (2015)